Research Progress on TRIM28 and GBM
DOI:
https://doi.org/10.54097/tdc7j328Keywords:
GBM, TRIM, TRIM28, TumorAbstract
Glioblastoma (GBM) is the most aggressive and deadly malignant glioma of the adult central nervous system (CNS), making the discovery of related genes essential for its treatment and prognosis. Recent study has shown that Tripartite motif (TRIM) is involved in several biological processes, both suppressing tumor formation and facilitating tumor growth and invasion. It may modulate the onset and progression of cancers via many methods. tripartite motif-containing protein 28 (TRIM28) is a member of the TRIM protein family, serving as a multifunctional transcriptional regulator that participates in chromatin remodeling, DNA damage repair, and the maintenance of stem cell pluripotency. Recent research indicates that TRIM28 influences the self-renewal and chemotherapy resistance of tumor stem cells via modulating the expression of tumor stem cell markers, including Prominin-1 (CD133) in GBM. Research demonstrates that TRIM28 directly engages with the promoter region of the CD133 gene via an epigenetic mechanism, inhibits histone acetylation (particularly h3k27ac), and therefore downregulates CD133 expression. The knockdown of trim28 might significantly reduce the stem cell properties of GBM cells, hinder tumor sphere formation, and enhance their sensitivity to temozolomide (TMZ). Subsequent study demonstrated that trim28 recruited histone deacetylase (HDAC) and DNA methyltransferase (DNMT) complexes to the CD133 promoter region, leading to localized chromatin compaction and gene silencing. This mechanism depends on the PhD bromo domain of TRIM28, signifying the specificity of its epigenetic regulatory function. Besides, there are also other mechanism that to do with TRIM28 and GBM. As for the therapeutic potential, TRIM28 can be used as a significant biomarker in GBM. Besides, CD133-targeted chimeric antigen receptor T cell may be a viable therapeutic approach to target CD133+ cancer stem cells in human glioblastoma or other treatment-resistant primary malignancies. Nonetheless, the precise mechanism of TRIM in GBM necessitates further investigation.
Downloads
References
[1] Afshar J, Mehrzad J, Mehrad-Majd H, Goshayeshi L, Saeidi J. Prognostic Significance of Tripartite Motif Containing 16 Expression in Patients with Gastric Cancer. Asian Pac J Cancer Prev. 2021. 22(8): 2445-2451.
[2] Singhal N, Agarwal V. Pediatric gliomatosis cerebri mimicking tubercular encephalitis. J Pediatr Neurosci. 2015. 10(4): 379-81.
[3] Chen R, Smith-Cohn M, Cohen AL, Colman H. Glioma Subclassifications and Their Clinical Significance. Neurotherapeutics. 2017. 14(2): 284-297.
[4] Vasilev A, Sofi R, Rahman R, Smith SJ, Teschemacher AG, Kasparov S. Using Light for Therapy of Glioblastoma Multiforme (GBM). Brain Sci. 2020. 10(2): 75.
[5] Tykocki T, Eltayeb M. Ten-year survival in glioblastoma. A systematic review. J Clin Neurosci. 2018. 54: 7-13.
[6] van Solinge TS, Nieland L, Chiocca EA, Broekman M. Advances in local therapy for glioblastoma - taking the fight to the tumour. Nat Rev Neurol. 2022. 18(4): 221-236.
[7] Aierken G, Seyiti A, Alifu M, Kuerban G. Knockdown of Tripartite-59 (TRIM59) Inhibits Cellular Proliferation and Migration in Human Cervical Cancer Cells. Oncol Res. 2017. 25(3): 381-388.
[8] TRIM11 Promotes Proliferation, Migration, Invasion and EMT of Gastric Cancer by Activating β-Catenin Signaling [Retraction]. Onco Targets Ther. 2024. 17: 731-732.
[9] Bhaduri U, Merla G. Ubiquitination, Biotech Startups, and the Future of TRIM Family Proteins: A TRIM-Endous Opportunity. Cells. 2021. 10(5): 1015.
[10] Hatakeyama S. TRIM Family Proteins: Roles in Autophagy, Immunity, and Carcinogenesis. Trends Biochem Sci. 2017. 42 (4): 297-311.
[11] Wei Y, Chen Q, Chen J, et al. Loss of α-1,2-mannosidase MAN1C1 promotes tumorigenesis of intrahepatic cholangiocarcinoma through enhancing CD133-FIP200 interaction. Cell Rep. 2023. 42(12): 113588.
[12] Wei Y, Chen Q, Huang S, et al. The Interaction between DNMT1 and High-Mannose CD133 Maintains the Slow-Cycling State and Tumorigenic Potential of Glioma Stem Cell. Adv Sci (Weinh). 2022. 9(26): e2202216.
[13] Kim YS, Potashnikova DM, Gisina AM, et al. TRIM28 Is a Novel Regulator of CD133 Expression Associated with Cancer Stem Cell Phenotype. Int J Mol Sci. 2022. 23(17): 9874.
[14] Rousseaux MW, de Haro M, Lasagna-Reeves CA, et al. TRIM28 regulates the nuclear accumulation and toxicity of both alpha-synuclein and tau. Elife. 2016. 5: e19809 [pii].
[15] Hamers-Casterman C, Atarhouch T, Muyldermans S, et al. Naturally occurring antibodies devoid of light chains. Nature. 1993. 363(6428): 446-8.
[16] Hassanzadeh-Ghassabeh G, Devoogdt N, De Pauw P, Vincke C, Muyldermans S. Nanobodies and their potential applications. Nanomedicine (Lond). 2013. 8(6): 1013-26.
[17] Ebrahimizadeh W, Mousavi Gargari S, Rajabibazl M, Safaee Ardekani L, Zare H, Bakherad H. Isolation and characterization of protective anti-LPS nanobody against V. cholerae O1 recognizing Inaba and Ogawa serotypes. Appl Microbiol Biotechnol. 2013. 97(10): 4457-66.
[18] Jovčevska I, Zupanec N, Kočevar N, et al. TRIM28 and β-actin identified via nanobody-based reverse proteomics approach as possible human glioblastoma biomarkers. PLoS One. 2014. 9(11): e113688.
[19] Cho WC. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol. 2010. 42(8): 1273-81.
[20] Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009. 136(2): 215-33.
[21] Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005. 120(1): 15-20.
[22] Nakano H, Miyazawa T, Kinoshita K, Yamada Y, Yoshida T. Functional screening identifies a microRNA, miR-491 that induces apoptosis by targeting Bcl-X(L) in colorectal cancer cells. Int J Cancer. 2010. 127(5): 1072-80.
[23] Zhou Y, Li Y, Ye J, et al. MicroRNA-491 is involved in metastasis of hepatocellular carcinoma by inhibitions of matrix metalloproteinase and epithelial to mesenchymal transition. Liver Int. 2013. 33(8): 1271-80.
[24] Qi Z, Cai S, Cai J, et al. miR-491 regulates glioma cells proliferation by targeting TRIM28 in vitro. BMC Neurol. 2016. 16(1): 248.
[25] Barzegar Behrooz A, Latifi-Navid H, da Silva Rosa SC, et al. Integrating Multi-Omics Analysis for Enhanced Diagnosis and Treatment of Glioblastoma: A Comprehensive Data-Driven Approach. Cancers (Basel). 2023. 15(12): 3158.
[26] Vora P, Venugopal C, Salim SK, et al. The Rational Development of CD133-Targeting Immunotherapies for Glioblastoma. Cell Stem Cell. 2020. 26(6): 832-844.e6.
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

